NattoPharma Secures U.S. Patent for Vitamin K2 in Heart-Healthy Food
NattoPharma says that the patent gives it “broad coverage” in the use of vitamin K2, also known as menaquinones, in these types of products.
NattoPharma ASA (Oslo, Norway) has obtained a U.S. patent covering the use of vitamin K2 in food products, including dietary supplements, for the purpose of “maintaining, optimizing, strengthening, or promoting cardiovascular health,” the company reports.
NattoPharma says that the patent gives it “broad coverage” in the use of vitamin K2, also known as menaquinones, in these types of products.
“The approval of the patent represents a milestone for NattoPharma and our partners in the U.S. market,” says company CEO Hogne Vik, PhD. “This will strengthen NattoPharma’s global IPR-platform and improve our competitive position in the United States within the food supplement market as well as the functional food market.”
The patent is No. 09/850,804: “Vitamin K2 Containing Food Product.” NattoPharma is the supplier of branded vitamin K2 ingredient MenaQ7.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
